Company ProfilePremium

Eternis Fine Chemicals Ltd.

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Eternis Fine Chemicals Ltd. - Company showcase

Year Founded & Workforce

1965

609 Employees

Eternis Fine Chemicals Ltd. logo

Eternis Fine Chemicals Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Eternis Fine Chemicals Ltd. Overview

AttributeDetailSource
Legal nameEternis Fine Chemicals Limited (EFCL)MCA via Zauba/Tracxn
Former nameHindustan Polyamides & Fibres Limited (HPFL); rebranded Eternis in 2015Sustainability Report 2023-24; Yahoo Finance/Newsfile release, 4-Dec-2024
Corporate Identification Number (CIN)U17120MH1965PLC015806 (registration no. 15806, ROC Mumbai)MCA via Zauba, Tracxn
Incorporation date25 February 1965MCA via Zauba, TheCompanyCheck, Bloomberg
Entry into aroma chemicals1988, through acquisition of a chemicals plant at Koregaon-Bhima, Pune. The company describes itself as "born in 1988".eternis.com "Our Story"
Incorporation jurisdictionMaharashtra, India (Companies Act)MCA
Registered office / HQ1004 Peninsula Tower, Peninsula Corporate Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013, Indiaeternis.com; Bloomberg
Company type (actual)Unlisted public limited company, closely held by the Mariwala family. Your list says "Public company". That is correct legally (Indian "public limited" status), but the company is not listed on any exchange.CRISIL rationales; TheCompanyCheck
Stock exchange / tickerNone (unlisted). The Bloomberg identifier 1512539D:IN is a private-company ID, not a trading ticker.Bloomberg
ISIN / CUSIPNot publicly disclosed. No exchange-traded security exists.—
Fiscal year end31 MarchCRISIL; MCA filings
Promoter holding94.38% promoters; 5.62% public/non-promoter (2023)TheCompanyCheck (MCA-derived)
Paid-up capital₹12.459 lakh (₹1,245,900); authorised capital ₹45.55 croreTracxn (MCA-derived), Nov-2025
Employees (latest)609 group employees in FY2024 (India 495, UK 114), before the Sharon PC acquisitionSustainability Report 2023-24
Employees (other data points)488 (Apr-2024, standalone); 493 (30-Sep-2024, standalone); "600+" (Dec-2024 press release); ~475 (LeadIQ, Mar-2026, likely LinkedIn-based). Sharon PC alone had 200+ staff in 2023.TheCompanyCheck; Tracxn; Newsfile; LeadIQ; Newsfile Jul-2023
Statutory auditorNot publicly disclosed in sources reviewed. It is available in MCA AOC-4 filings.—
Market capitalisationNot applicable (unlisted). No observable valuation.—
Credit ratingCRISIL A+/Stable (long-term); CRISIL A1 (short-term). Last full rationale Dec-2024; reiterated in Nov-2025.CRISIL
Websiteswww.eternis.com (group/India); www.eternis.co.uk (UK); www.sharonpc.com (personal care, now Eternis Personal Care)Company
Last AGM6 June 2025Tracxn / TheCompanyCheck (MCA)

The name on the request, "Eternis Fine Chemicals Ltd.", matches an active Indian legal entity exactly. The dossier profiles that entity and its consolidated group.

MetricFY2023FY2024FY2025
Group employees, India + UK (count)—609—
Standalone India employees (count)—495493

FY2023 and FY2025 group counts are not publicly disclosed. The FY2025 standalone figure is Tracxn as of 30-Sep-2024. A post-acquisition consolidated headcount including Sharon PC has not been published.

Eternis Fine Chemicals is a Mumbai-headquartered, Mariwala-family-controlled maker of aroma chemicals: the synthetic fragrance molecules that global flavour and fragrance (F&F) houses blend into perfumes, detergents, soaps and personal care products. It is part of the same promoter family as Marico Limited and positions itself as India's largest aroma-chemical exporter and a top-10 global producer. The company also describes itself as a top-5 independent aroma-ingredient company. Its customers include all four of the largest F&F houses: Givaudan, IFF, Firmenich (now dsm-firmenich) and Symrise. Manufacturing capacity is about 75,000 tonnes per year across four Maharashtra plants and Leek, UK. Through the December 2024 acquisition of Sharon Personal Care, rebranded Eternis Personal Care in July 2026, it has added a second business leg in cosmetic preservatives and functional ingredients, with a plant in Italy. Consolidated revenue is roughly ₹1,900–2,300 crore (about US$230–270 million). It is a commodity-to-specialty bridge player whose edge is scale in a few molecules, cost position, and its status as a supplier to the F&F majors.


What the company does

Eternis makes aroma chemicals. These are single-molecule, synthetic or nature-identical odorants such as coumarin, benzyl salicylate, hexyl cinnamic aldehyde, cyclamen aldehyde, phenyl ethyl alcohol, styrallyl acetate and the PTBCHA/OTBCHA cyclohexyl acetates. They are sold as building-block ingredients to fragrance compounders, who formulate them into fragrance oils for consumer goods.

The UK subsidiary at Leek adds aroma chemicals and acetate ester chemicals. Its liquid products serve lubricants, metalworking fluids, surface coatings, cosmetics, oilfield, pharma, paints, leather, explosives, paper, plastics, food and feed, inks, plasticiser replacements and textile auxiliaries (eternis.co.uk).

Since December 2024 the group also makes personal care ingredients through Eternis Personal Care (ex-Sharon Personal Care). The range covers preservative systems, multifunctional ingredients, actives, textures, wet-wipe solutions and sun-care ingredients (Personal Care Magazine / Cosmetics Business, Jul-2026).

Business and revenue model

DimensionCharacterisationEvidence
Revenue typeAlmost entirely product sales. Bulk and specialty chemicals are sold in drums, IBCs and containers. There is no subscription, licensing or service revenue of note.Product pages; US import manifests show drum/FCL shipments
PricingContract and spot pricing with large F&F houses. Raw materials are phenol- and crude-linked. Management has adopted formula-based pricing with key suppliers to reduce margin volatility.Sustainability Report 2023-24; CRISIL
Customer concentrationPreferred supplier to Givaudan, IFF, Firmenich and Symrise. At the UK site, 72% of sales go to multinationals.CRISIL (2022–2024); eternis.co.uk
Product concentrationTop six products make up a sizeable share of turnover. Hydrogenation-chemistry products and salicylates were about half of revenue (FY2022–23) and about one-third (per Dec-2024 rationale).CRISIL Jul-2022, Oct-2023, Dec-2024
Export orientationAbout 75% of turnover is exported (CRISIL, FY2022–FY2024); the company itself states 80%.CRISIL; company
Contract manufacturingA historic co-production alliance with Firmenich for Hedione® (2005–09). The CEO has signalled an aim to be an "OEM manufacturer of choice".eternis.com; P&F+ interview, 2024

Value-chain position

Eternis sits in the middle of the fragrance value chain:

Upstream: petrochemical intermediates (phenol, toluene derivatives, aldehydes, acetic acid), hydrogen (produced on-site in a captive plant) and palm-derived oleochemicals (100% RSPO mass-balance certified).

Midstream (Eternis): multi-step chemical synthesis, including hydrogenation, esterification, condensation and distillation.

Downstream customers: fragrance houses compound Eternis molecules into fragrance oils. These are then sold to FMCG brand owners (home care, personal care, fine fragrance).

With Eternis Personal Care, the group also sells directly to cosmetic formulators and brand owners. The SO.F.I.A Cosmétiques joint venture, which offers formulation and finished-product manufacturing in France, extends the group one step further downstream.

End-markets

End-marketExposureComment
Functional fragrance (detergents, soaps, household care)CoreCRISIL describes this as a "relatively stable" segment that cushions product-concentration risk
Fine fragranceCoreThe company says its products go into many leading perfumed brands
Personal care / cosmetics (preservatives, actives, textures, wet wipes, sun care)New since Dec-2024Via Eternis Personal Care
Food and feed / flavoursEmergingFSSAI food licence granted for the Kurkumbh plant; UK food-grade approval expected mid-2025
Industrial (lubricants, coatings, inks, plastics, explosives, leather, paper)UK siteAcetate esters and liquid chemicals from Leek

Company self-description vs. independent characterisation

Company self-description. No public annual report is available. In its Sustainability Report 2023-24, the company presents itself as a manufacturer of fragrance and personal-care ingredients and states its purpose as "Enriching Lives with Care". Its corporate "DNA" is "Eternally Agile, Forever Customer-Centric". It cites roughly US$233 million in annual sales, 65,000 tonnes of capacity and 80% export share, and calls itself a top-5 independent aroma-ingredient company.

Independent characterisation. Eternis is a mid-sized, export-led, scale-commodity aroma chemicals producer working to move up the specialty curve. Its margins have historically been modest for a specialty chemical company: operating margin of 10–15% and PAT margin of 3.4–4.9% over FY2021–FY2024 (CRISIL). That is well below listed Indian peer Privi Speciality, at roughly 22–26% EBITDA. The gap reflects the lower-margin UK business, raw-material pass-through lags, and intense competition from China and from the backward-integrated F&F majors.

The 2024–2026 strategy has four parts:

  • a France-based professional CEO;

  • the personal-care acquisition;

  • the downstream SO.F.I.A joint venture;

  • a sustainability-led premium (low-carbon product variants, TfS membership).

Together these amount to a deliberate effort to escape commodity economics. Execution is unproven in public data.

Strategy

Stated strategy themes

Drawn from the CEO interview (P&F+, 2024), the Sustainability Report 2023-24 and the 2024–2026 releases.

  1. Grow the core aroma-chemicals business. Keep investing in capacity, molecules and agility. The company aims to be an OEM / contract manufacturer of choice for F&F houses.

  2. Build a "second leg" in an adjacent market. The CEO flagged this in 2024; it was executed via Sharon Personal Care (Dec-2024) and the SO.F.I.A JV.

  3. Sustainability as a differentiator. Goals include 67% renewable energy, LCAs on more than 80% of products, low-PCF alternatives for 90% of products by 2028, an SBTi-aligned decarbonisation plan, TfS membership, and capturing waste hydrogen as fuel.

  4. Customer centricity and digitalisation. Initiatives cover a dedicated NPD team, a deep-sea shipment tracker, a CRM rollout (2025), a global SAP rollout (2025) and harmonised quality standards across sites.

  5. Organisation building. The company is adding professional global leadership (CEO, CHRO, Head of Procurement, Head of HR Manufacturing) under the purpose "Enriching Lives with Care" and the DNA "Eternally Agile, Forever Customer-Centric."

Initiatives in the last 24 months (Oct-2024 to Oct-2026)

InitiativeDateDescriptionStatus
Acquisition of Sharon Personal CareDec-2024Entry into personal-care ingredientsIntegrated; rebranded Jul-2026
ECPL amalgamationFiled Mar-2025Structural simplificationCompleted
ChainCraft collaborationMar-2025Low-carbon, bio-based aroma chemicals using ChainCraft's SensiCraft® fatty acidsDevelopment stage
TfS membership2,025Supply-chain sustainability audits; first Indian memberActive
SO.F.I.A Cosmétiques JV2025–26Integrated formulation and manufacturing in FranceAnnounced; financials undisclosed
Trezzo SPC-1 plant2,025New 7,500 t/yr personal-care plantOperational
Global CHRO and procurement build-outJun-2025 / Apr-2026People and procurement transformationOngoing
SAP and CRM rollout2,025Standardised operationsPlanned per SR; completion not reported
UK food-grade approvalExpected mid-2025Food-grade facility in the UK (India approved)Not confirmed
ISCC+ for all sitesTarget 2025Mass-balance bio-attributed productsLeek certified; group status not confirmed
Eternis Personal Care rebrandJul-2026Unified global brandCompleted

Sustainability targets (company-stated)

TargetDeadlineBaseline
30% reduction in Scope 1+2 GHG intensity2,030FY2023
90% reduction in Scope 1+2 GHG intensity; Net Zero2,050FY2023
30% reduction in Scope 3 intensity2,0302,023
Zero waste to landfill2,030—
30% reduction in waste intensity2,0302,023
2% per year reduction in freshwater intensityOngoing to 2030—
90% of products with a lower-PCF alternative2,028—
80% of raw-material spend assessed on ESG2,028—
TRIR below 0.3 (another section of the report says below 0.2)2,030—
EcoVadis Ethics score of 702,030—

Medium-term financial targets / guidance

Not publicly disclosed. The only forward markers in the public domain are third-party:

  • CRISIL expected operating margin of about 13% over the medium term (Dec-2024).

  • CRISIL's upgrade trigger is 14–16% margin; its downgrade trigger is margin below 10%.

  • CRISIL expected debt/EBITDA of 2.5–2.7x by end-FY2026.

Products & Services

All India-made aroma products are EU REACH-registered and Kosher-certified (eternis.com). Halal certification and RSPO/ISCC+ chain-of-custody certifications are also held (Sustainability Report). Pricing is not publicly disclosed for any product.

Eternis Aroma Chemicals: India portfolio

ProductDescription / olfactive roleCapabilities and notesTarget customerLaunch / scale-upSource
CoumarinSweet, hay-like, tonka note; widely used in fougère and oriental accords and in functional fragranceStrengthened by the 2018 AIMS Impex acquisition. Eternis became India's only coumarin manufacturer, with AIMS reportedly holding ~50% of the Indian market. Base capacity was ~1,500 t before the deal.F&F houses globallyEternis entry pre-2018; AIMS acquired 2018eternis.com; Avendus; Outlook Business; CB Insights
PTBCHA (p-tert-butylcyclohexyl acetate)Woody-floral, fruity; high-volume functional ingredientHydrogenation chemistry using the captive hydrogen plantF&F houses1990seternis.com
PTBCHA Super / Hi-CisHigh-cis isomer grade with a stronger, more valued odourIsomer-control capabilityFine and functional fragrance2000–04eternis.com
PTBCH (p-tert-butylcyclohexanol)Intermediate / woody noteHydrogenationF&F—eternis.com
OTBCHA (o-tert-butylcyclohexyl acetate)Fruity-woody, apple-likeHydrogenationF&F1990seternis.com
OTBCHA SuperHigh-performance isomer gradeIsomer controlF&F—eternis.com
Styrallyl AcetateGreen, gardenia-like floralShipped in volume to the US (e.g., Givaudan Fragrances Corp., Jul-2025 manifest)F&F1990seternis.com; ImportInfo
Benzyl SalicylateFaint balsamic-floral fixative; very high volumeSalicylate chemistry; along with hydrogenation, one of the two families that historically drove a large share of revenueF&F2000–04eternis.com; CRISIL
Hexyl SalicylateGreen-floral, herbaceousSalicylate chemistryF&F2000–04eternis.com
HamberAmbery-woody (trade name)Specialty moleculeF&F2005–09eternis.com
Hexyl Cinnamic Aldehyde (HCA)Jasmine-like floral; high volumeCondensation chemistryF&F2010–14eternis.com
Cyclamen Aldehyde PureFresh-floral, cyclamen/lily-of-the-valleyShipped to Mane USA (Jul-2025 manifest)F&FLaunched 2015eternis.com; ImportInfo
Phenyl Ethyl Alcohol (PEA)Rose-like floral; also a preservative booster in cosmeticsPlant scale-up from 2015; cross-sold into personal care as "Sharon PA"F&F; cosmetics2,015eternis.com; SpecialChem
TMCHTrade abbreviation; molecule not disclosed in sources—F&F2000–04eternis.com
Butyl cyclohexyl acetateFruity-woodyListed by Bloomberg and EPCAF&F—Bloomberg; EPCA
Hedione® (co-production)Methyl dihydrojasmonate (Firmenich trademark); jasmine-transparentCo-production alliance with Firmenich, 2005–09. The company notes the arrangement ended because the partner wanted extra capacity without investing. Current status not disclosed.Firmenich2005–09eternis.com; Outlook Business

Eternis Aroma Chemicals: UK (Leek) portfolio

Product familyDescriptionApplicationsNotesSource
Aroma chemicalsIncludes benzyl benzoate and benzyl salicylatePerfumery and cosmeticsLeek is described as the UK's largest aroma-chemical producerC&EN 2021; eternis.co.uk
Acetate ester chemicalsLiquid estersLubricants, metalworking fluids, coatings, paints, inks, pressroom chemicals, phthalate-plasticiser replacements, plastics, paper, leather, textiles, emulsion explosives, oilfield, pharma, food and feed, tobaccoClaims exports to almost 90 countries; ~24,000 t/yr outputeternis.co.uk

None of the substances produced at Leek fall into PBT, vPvB or endocrine-disruptor categories (Sustainability Report).

Eternis Personal Care (ex-Sharon Personal Care) portfolio

Product / platformDescriptionTarget customerLatest updateSource
Sharon PA (phenethyl alcohol)Solvent / preservative booster; globally approved; free of parabens, formaldehyde donors and isothiazolinonesCosmetic formulatorsListing updated Jul-2026 under the Eternis Personal Care brandSpecialChem
Sharon E50 (ethylhexylglycerin)Emollient and preservative booster for broad-spectrum protectionCosmetic formulatorsListing updated Jul-2026SpecialChem
Broad-spectrum preservative systemsCore heritage of Sharon Laboratories (founded 1977)Personal care, wet wipesOngoingNewsfile 2023; PCM 2026
Active ingredientsSkincare activesBrand owners / formulatorsOngoingPCM 2026
Textures and Texture SelectorGlobal tool to simplify texture formulationFormulatorsLaunched mid-2026HPC Mag MEA, Jul-2026
Wet-wipes solutionsLotions and preservation for wipesWipes convertersOngoingCB Insights (RES Pharma deal context); PCM
Sun-care ingredientsSun-care functional ingredientsSun-care brandsOngoingPCM 2026
Multifunctional ingredientsMulti-benefit functionals for next-generation formulationsFormulatorsOngoingPCM 2026

Manufacturing for personal care is now cited as Italy, India and the UK (PCM, Jul-2026), which suggests cross-loading onto the legacy Eternis plants.

Services

Application labs: Italy and US. Sharon opened a US application lab and sales office in 2023.

Microbiology research lab: Israel.

Regulatory dossier support: REACH registrations and downstream-user safety communication.

Product carbon footprint (PCF) data: LCAs completed for more than 80–90% of products.

Low-carbon variants: Lower-PCF product alternatives, with a target that 90% of products have a lower-PCF alternative by 2028.

Turnkey beauty: End-to-end formulation-to-finished-product services via the SO.F.I.A Cosmétiques JV.

None is monetised separately in disclosed data.

Financial Narrative

Data basis. All figures are consolidated (Eternis + UK subsidiaries ± ECPL) as presented in CRISIL rationales, which are drawn from audited financials but analytically adjusted (e.g., CRISIL amortises acquisition goodwill over five years). Because there is no public annual report, the following are not publicly disclosed: gross profit, EPS, dividends per share, reported EBITDA and segment data. Blank cells mean "not publicly disclosed." FY2025 actuals have not been published by CRISIL in sources reviewed; the FY2025 revenue shown is CRISIL's December-2024 projection, corroborated by Tracxn's MCA-derived ₹2,300 crore figure.

Income statement

Sources: CRISIL rationales of 6-Jul-2022 (FY2021, FY2022 margin), 4-Oct-2023 (FY2022 restated income, FY2023), 13-Dec-2024 (FY2024; FY2025 projection ~₹2,300 crore). FY2022 income is ₹1,895 crore in the Jul-2022 rationale versus ₹1,902 crore in Oct-2023; the latter is used. The FY2022 growth figure (76%) is CRISIL's own. EBITDA is derived.

Revenue CAGR (derived): FY2021→FY2024 ≈ 21% (₹1,079 → ₹1,911 crore), mainly inorganic from Tennants. FY2022→FY2024 ≈ 0%, reflecting flat organic revenue through the destocking cycle. FY2021→FY2025 (projection) ≈ 21%.

Commentary.

FY2022: Revenue rose 76%, driven by a full year of Tennants plus volume growth and higher realisations. Margin fell from 14.7% to 10.4% on raw-material and energy inflation and the lower-margin UK mix.

FY2023: Revenue grew 6%, almost entirely on price. Volumes were weak as the value chain had over-stocked during the oil spike. UK operations suffered from high energy costs. Margin held at 10.2%.

Q1 FY2024: Margin fell to about 8% as the UK business was hit by Chinese dumping of specialty chemicals.

FY2024: Revenue fell about 6% to ₹1,911 crore as crude-linked raw-material prices fell and passed through to realisations, while global F&F houses destocked amid US and European slowdowns. Margin nevertheless rebounded to 13.2% on cheaper inputs, and PAT rose to ₹94 crore. Indian volumes grew 14%.

H1 FY2025: Revenue grew about 13% with ~14% margins.

FY2025: The acquisition of SPC was expected to lift reported revenue to ~₹2,300 crore.

Data conflicts (FY2025–FY2026):

  • Tracxn's MCA-derived table shows irregular revenue numbers (5896, 5893, 7422, 3363, 3853) with no unit stated. These are irreconcilable with CRISIL and are disregarded.

  • Tofler lists standalone FY2026 operating revenue in a ₹1,500–1,750 crore band, with total revenue up 5.61% and EBITDA up 3.69%. This is consistent with a standalone (India-only) figure and is not comparable with the consolidated series above.

  • TheCompanyCheck reports a 3.09% revenue drop and 16.99% profit rise for "FY2024". This direction matches CRISIL; the magnitude differs, plausibly standalone vs consolidated.

Balance sheet

Notes:

  • FY2025 values are CRISIL projections made in Dec-2024 to capture acquisition debt; they are not reported actuals.

  • Net worth ₹813 crore is CRISIL's "adjusted networth" (Dec-2024 rationale, reflecting the Mar-2024 balance sheet).

  • An FY2023 net worth of ~₹707 crore is implied by 431 / 0.61 (derived; not shown in the table because CRISIL's gearing definition is "adjusted").

  • Not publicly disclosed: goodwill and intangibles, working capital in absolute terms, short- vs long-term debt split.

Debt composition evidence. Rated bank lines total ₹765 crore: working-capital facilities of ₹717.5 crore (Citibank ₹180 crore, Standard Chartered ₹160 crore, JP Morgan ₹125 crore, HDFC Bank ₹100 crore, DBS ₹77.5 crore, HSBC ₹75 crore) plus a Citibank standby letter of credit of ₹47.5 crore (CRISIL, Dec-2024). Earlier term debt (rupee term loans, FCTL and ECB from HDFC, Citi and HSBC) had largely amortised by Jan–Mar 2024 (CRISIL Oct-2023). The Sharon PC acquisition debt sits outside these rated lines; its quantum is not publicly disclosed. CRISIL expects it to have a long maturity.

Commentary.

Peak gearing (Mar-2021): 1.4–1.5x, after the debt-funded Tennants purchase.

Deleveraging (FY2022): Promoter equity infusion and accruals allowed ₹220 crore of prepayment, reducing gearing to 0.7x by FY2022 and 0.38x by FY2024.

Re-leveraging (FY2025): The Sharon PC deal re-levers the balance sheet. CRISIL projected debt/EBITDA of 4.72x at Mar-2025. It expected promoter equity to fund prepayment of 40–50% of the acquisition debt by November 2025, bringing debt/EBITDA to ~2.5–2.7x by end-FY2026.

Equity infusion status: Whether that infusion occurred is not publicly confirmed. PitchBook records a US$47.3 million "later stage" equity deal dated 14-May-2025 with one investor. That is consistent in timing and size (~₹400 crore) with a promoter infusion but is unconfirmed by the company. CRISIL's Nov-2025 reference to Eternis as still "Crisil A+/Stable" implies no rating stress.

Cash flow

Notes: Accrual figures are CRISIL forward-looking ranges (₹140–150 crore in Oct-2023; ₹200–250 crore in Dec-2024) shown at midpoint against the year of the rationale. Utilisation is 56% (FY2022), 69% (15 months to Jul-2023), and 54% (12 months to Sep-2024). Not publicly disclosed: operating cash flow, reported capex, free cash flow, dividends paid, buybacks. CRISIL notes promoters have extended timely liquidity support when needed.

Ratios

Notes: ROE FY2023 = 70 / ~707 (derived); FY2024 = 94 / 813. Debt/equity FY2025 is a CRISIL projection. Working-capital days are from CRISIL (Mar-2022 and Mar-2024). Not publicly disclosed: ROA, ROIC, current ratio, asset turnover.

Ratio commentary. Returns are modest. A ~10–12% ROE on a ~₹800 crore equity base, and PAT margins under 5%, show that Eternis has scale without specialty-grade pricing power. That is the core analytical issue for the business. Working capital is heavy, at roughly 160 days of receivables plus inventory, typical of an exporter serving multinational F&F houses on extended terms. Credit metrics in FY2024 were the strongest in the five-year window, which supported the A+ rating and gave headroom for the Sharon PC deal.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipRoleSource

Eternis Fine Chemicals Ltd (India)

Parent

Indian manufacturing (Kurkumbh, Koregaon-Bhima, Sinnar, new greenfield site), R&D, HQ

CRISIL

Eternis Chemicals Pvt Ltd

Former 100% subsidiary; amalgamated into parent (order filed with ROC 21-Mar-2025)

Greenfield plant near Pune

CRISIL Nov-2025

AIMS Impex Pvt Ltd

Former subsidiary; merged into parent effective June 2018

Coumarin, Sinnar (Nashik)

CRISIL

Eternis UK Ltd

100% subsidiary

UK holding and export marketing arm; acquisition vehicle for Sharon PC

CRISIL Dec-2024; CARE 2022

Eternis Fine Chemicals UK Ltd (ex-Tennants Fine Chemicals)

Step-down 100% subsidiary via Eternis UK Ltd

Leek manufacturing (aromas and acetate esters)

CRISIL

Singapore and China subsidiaries (ex-Tennants)

Step-down subsidiaries

Regional distribution / service hubs

P&F+ 2021

Eternis Personal Care (ex-Sharon Personal Care), including Sharon Personal Care Srl (Trezzo sull'Adda, Italy)

Acquired 100% Dec-2024 via Eternis UK Ltd

Personal-care ingredients

CRISIL; eternis.com

Eternis Fine Chemical USA LLC

Affiliate / importer of record (named as consignee on US import records)

US distribution hub

ImportInfo (bills of lading)

SO.F.I.A Cosmétiques JV

Joint venture (stake undisclosed)

Cosmetic formulation and manufacturing, France

SOFW / P&F+

Business Units

Business unit (management view)ContentsSegment revenueSegment profit / marginShare of total

Eternis Aroma Chemicals: India

Coumarin, salicylates, hydrogenation products (PTBCHA/OTBCHA/PTBCH), cyclamen aldehyde, HCA, Hamber, PEA, styrallyl acetate

———

Eternis Aroma Chemicals: UK (Leek)

Aroma chemicals (e.g., benzyl benzoate, benzyl salicylate) and acetate esters; ~24,000–26,000 t/yr

Not publicly disclosed post-acquisition. At acquisition (2021), Tennants had ~US$85m / ~£62m annual sales.

Lower than India per CRISIL; hit by energy costs (FY2023) and Chinese dumping (Q1 FY2024)

—

Eternis Personal Care

Preservatives, multifunctionals, actives, textures, wet-wipe and sun-care solutions; Italy plant; Israel microbiology lab; US, DE, FR distribution

——

CRISIL projected that consolidated FY2025 revenue including SPC would reach ~₹2,300 crore vs ₹1,911 crore in FY2024

“—” = not publicly disclosed.

Operating Metrics (tonnes) and Revenue by Segment (%)

MetricFY2021FY2022FY2023FY2024FY2025

Group aroma capacity (tonnes per annum)

66,00066,00066,00065,00075,365

Total group production volume (tonnes)

——50,85451,209—

UK site annual output claimed (tonnes)

24,00024,000———

Exports as % of consolidated turnover (%)

—757575—

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Operating income, consolidated (INR Cr)

1,0791,9022,0231,9112,300

Revenue growth YoY (%)

—766-620

Operating (EBITDA-basis) margin (%)

14.710.410.213.2—

EBITDA, derived = income × margin (INR Cr)

159197206252—

Profit after tax (INR Cr)

38707094—

PAT margin (%)

3.53.73.44.9—

Interest coverage (times)

6.035.134.147.02—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Ratios (x) and Income Statement

MetricFY2021FY2022FY2023FY2024FY2025

Adjusted debt / adjusted net worth (times)

1.390.700.610.381.67

Total debt / EBITDA (times)

——2.091.214.72

Total debt, derived = debt/EBITDA × EBITDA (INR Cr)

——431305—

Adjusted net worth (INR Cr)

———813—

Cash and marketable securities (INR Cr)

———145—

Net debt, derived (INR Cr)

———160—

Cash Flow and Margin Analysis (%)

MetricFY2022FY2023FY2024

Net cash accruals, CRISIL estimate range midpoint (INR Cr)

—145225

Planned annual capex, CRISIL expectation (INR Cr)

805050

Debt repaid / prepaid (INR Cr)

220——

Average bank-limit utilisation (%)

566954

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE, derived = PAT / year-end adjusted net worth (%)

——9.911.6—

Interest coverage (times)

6.035.134.147.02—

Debt / equity (times)

1.390.700.610.381.67

Net debt / EBITDA, derived (times)

———0.63—

Receivable days

—90—85—

Inventory days

—81—70—

Payable days

—83———

Cash conversion cycle, derived (days)

—88———

Revenue by Region (%)

RegionFY2022FY2023FY2024

Exports, % of consolidated turnover (%)

757575

Domestic India, % of consolidated turnover (%)

252525

Region Overview

RegionEvidence of activityTrend signal

North America

Eternis Fine Chemical USA LLC importer; 2,608 US bills of lading Mar-2019 to Jul-2025, with consignees including Givaudan Fragrances Corp. and Mane USA; Sharon PC US warehouse (Parsippany, NJ) and application lab

Growing: Sharon PC's 2023 US expansion plus Eternis US hub

Europe

Leek (UK) manufacturing; Netherlands hub; sales teams in the Netherlands, Spain and France; Italy plant; Germany and France distribution (SPC); SO.F.I.A JV (France)

Mixed: UK margins pressured by energy costs and Chinese dumping (FY2023–24); personal care adds scale

India

4 plants; domestic F&F customers; volumes +14% in FY2024

Strong per CRISIL Dec-2024

Asia-Pacific ex-India

Singapore hub; China subsidiary (ex-Tennants)

Personal care to be pushed into APAC via Eternis' network (Sharon PC CEO, Dec-2024)

Middle East

Israel microbiology / innovation lab (Sharon heritage)

Israel no longer named as a manufacturing location in the Jul-2026 rebrand release; status unclear

Capital Markets

ItemStatus

Share price performance (1/3/5-year)

Not applicable: unlisted

Valuation multiples (P/E, EV/EBITDA, EV/Sales, P/B)

Not applicable. No traded equity; acquisition prices undisclosed. Listed peer Privi traded at ~₹2,352 per share around mid-2025 (Nuvama), with a market cap of ~₹6,669 crore at Mar-2025 (Blinkx), giving a reference for sector multiples.

Analyst consensus

None (no coverage)

Buybacks

None disclosed

Equity issuance

Promoter infusion FY2022 (amount used for ₹220 crore prepayment); possible US$47.3m equity, May-2025 (PitchBook; unconfirmed)

Moody's / S&P / Fitch

Not rated

Domestic ratings

CRISIL A+/Stable (long-term), CRISIL A1 (short-term); CARE ratings withdrawn Mar-2022

Debt maturity profile

Rated lines are mainly short-term working capital (₹717.5 crore); legacy term loans matured Jan–Mar 2024; acquisition debt expected to have long maturity (CRISIL); details not publicly disclosed

Capital Markets Data

Metric201820192021202220232024

CRISIL long-term rating notch (A-=1, A=2, A+=3)

122233

Total rated bank facilities (INR Cr)

345.84—651.4765765765

Analyst Conclusions

Management guidance

No public financial guidance exists. Proxy expectations from CRISIL (Dec-2024):

  • Consolidated revenue of ~₹2,300 crore in FY2025 including Sharon PC.

  • Operating margin of about 13% over the medium term.

  • Annual cash accruals of ₹200–250 crore.

  • Debt/EBITDA falling to 2.5–2.7x by end-FY2026, contingent on promoter equity.

Consensus

None. The company has no analyst coverage.

Bull case

  1. Margin re-rating via mix. FY2024 showed 13.2% operating margin even on falling revenue. Adding higher-value personal-care ingredients, lower-PCF premium variants and food-grade products could push margins into CRISIL's 14–16% upgrade band. That would roughly double PAT margin from sub-5%.

  2. Structural China+1 and ESG pull. EcoVadis Gold/Silver, first-Indian TfS membership, and LCAs across most of the portfolio align Eternis with the Scope 3 agendas of Givaudan, dsm-firmenich, IFF and Symrise. The multi-country footprint (India, UK, Italy) is a supply-security asset few independents can match.

  3. Professionalised platform with patient capital. The board and executive team now include an ex-DSM Personal Care & Aroma CEO and an ex-Symrise global president, alongside new global HR and procurement heads. Together with a 94%-owning promoter with a record of injecting equity, this supports further M&A and capacity growth without equity-market constraints.

Bear case

  1. Commodity economics persist. Organic revenue was flat from FY2022 to FY2024. Margins swing with phenol and crude, and Chinese competition caps pricing. A ~10–12% ROE suggests the business barely earns its cost of capital.

  2. Acquisition leverage and integration opacity. The Sharon PC price and returns are undisclosed. Leverage was projected at 4.7x debt/EBITDA, and completion of the promised promoter infusion is publicly unconfirmed. Personal-care preservatives is a crowded field dominated by larger specialists.

  3. Customer and product concentration. Four buyers dominate demand and can integrate backward, as the ended Hedione® alliance illustrates. Two chemistries (hydrogenation and salicylates) still carry about a third of revenue.

Catalysts and monitorables (next 12 months)

MonitorableWhy it matters
Next CRISIL surveillance rationale (FY2025/FY2026 actuals)First public read on post-acquisition leverage, margins and revenue
Confirmation of promoter equity infusion / acquisition-debt prepaymentKey rating sensitivity
FY2026 consolidated filing with MCA (AOC-4)Segment and personal-care contribution
Eternis Personal Care growth in APAC / IndiaValidates the cross-selling thesis
SO.F.I.A JV first commercial winsDownstream strategy proof-point
Leek UK profitability (energy, China competition)Largest drag historically
ChainCraft / low-carbon product commercialisationESG premium monetisation
Any further debt-funded M&AExplicit CRISIL downgrade trigger
Scope 1+2 trajectory vs. the 2030 targetCredibility of the ESG positioning

Analyst verdict

Eternis Fine Chemicals is a credible, well-capitalised but structurally low-return aroma-chemicals manufacturer in the middle of a strategic transition. Over six decades the Mariwala family has built it from an oleochemicals and polyamides heritage into a scale supplier of commodity-to-semi-specialty fragrance molecules. It reaches every major F&F house, runs about 75,000 tonnes a year of capacity across India and the UK, and holds ESG credentials that lead its Indian peer group.

The financial record tempers that franchise value. Revenue grew at about 21% a year from FY2021 to FY2024, but almost entirely through the Tennants acquisition; organic revenue was flat from FY2022 to FY2024. Operating margins of 10–15% and PAT margins under 5% trail Privi Speciality, whose 22–26% EBITDA margins show what product focus and cost leadership can achieve in the same market. Eternis's A+ credit rating reflects balance-sheet conservatism and promoter backing more than earnings power.

The 2024–2026 programme is the right response. It brings a seasoned DSM/IGM chief executive, a personal-care second leg via Sharon (now fully rebranded), a downstream JV in France, and decarbonised products as a commercial lever. Whether these lift returns is still unproven in public data.

The binding constraint for any outside stakeholder is disclosure. With no public annual report, the two most important questions remain unanswered: whether the promised promoter equity was injected, and what Eternis Personal Care contributes. Until those are confirmed, Eternis should be viewed as a stable, investment-grade-equivalent counterparty (CRISIL A+) with moderate execution risk in its diversification. Its operating profile is improving but not yet differentiated. For suppliers and customers it is a dependable partner. For potential investors or acquirers, valuation would hinge on proof that margins can move sustainably above 14%.


Principal sources consulted

  • CRISIL Ratings rationales: 7-Jun-2018; 6-Oct-2021; 6-Jul-2022; 4-Oct-2023 (EFCL and ECPL); 13-Dec-2024 (EFCL and ECPL); 13-Nov-2025 (ECPL withdrawal)

  • CARE Ratings press release on Eternis Fine Chemicals, 22-Mar-2022

  • Eternis Fine Chemicals Sustainability Report 2023-24 (eternis.com PDF); eternis.com (Our Story, Products, News); eternis.co.uk

  • Newsfile / Yahoo Finance release, 4-Dec-2024 (Sharon PC acquisition); Global Cosmetics News; Personal Care Insights; GCI Magazine; Happi; AlchemPro

  • Personal Care Magazine, Cosmetics Business and HPC Mag MEA (Jul-2026 rebrand); Cosmetics Business (Trezzo plant); SpecialChem product listings

  • Perfumer & Flavorist+ (CEO interview 2024; Tennants 2021; SO.F.I.A; company page); SOFW; Euro Cosmetics Magazine

  • World Bio Market Insights (ChainCraft, Mar-2025); PITCCH case study; CERE

  • C&EN (Feb-2021); Invest Staffordshire; Lawyer Monthly; Avendus; Outlook Business; CB Insights; Owler

  • MCA-derived aggregators: Zauba Corp, Tofler, Tracxn, TheCompanyCheck; Bloomberg, PitchBook, Crunchbase, ZoomInfo, RocketReach, LeadIQ profiles

  • LinkedIn company posts; Indian Chemical News; HR Today (Apr-2026, Jul-2026); ImportInfo US customs records

  • Peer data: Nuvama Q4FY25 chemicals review; Whalesbook and ScanX (Privi FY2026); Simply Wall St (Oriental Aromatics FY2025); Blinkx; Wikipedia (Together for Sustainability member list)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / backgroundSource

Rajendra (Rajen) K. Mariwala

Promoter & Managing Director

MD since 1-Apr-1995

Mariwala family; President of the Indian Chemical Council (per Sustainability Report)

TheCompanyCheck; Sustainability Report

Wilfrid Gambade

Group CEO (France-based)

Since Apr-2024

CEO IGM Resins (2021–24, PE-owned); DSM: President Protective Materials (2018–21), President Personal Care & Aroma Ingredients (2014–17), President Composites & Synres (2011–14); earlier Huntsman, Ciba Specialty Chemicals (EU, US), Allied Colloids

Indian Chemical News; ContactOut; P&F+

Chetan D. Chowatia

Chief Financial Officer (KMP)

Since 25-May-2023

—

TheCompanyCheck

Shailendra Arora

Whole-time Director

Since 25-Jun-2025

—

TheCompanyCheck

Krishan K. Sharma

Whole-time Director (per SR 2023-24)

——

Sustainability Report; Zauba

Billy Gittins

VP Strategy, Marketing & Product Management

Since 2021 (ex-MD Tennants Fine Chemicals)

Board member, UK Chemical Industries Association

P&F+; Sustainability Report

David Whitaker

VP New Product Development & Product Management

—

Chair, IFRA UK

Sustainability Report

Hari Menon

Global Chief Human Resources Officer

Since Jun-2025

Previously Mitsui O.S.K. Lines

People Matters via ZoomInfo/LeadIQ

Robert Monti

President, Eternis Personal Care

From 2026 rebrand

—

Personal Care Magazine

Naama Eylon

Former CEO/President, Sharon Personal Care

Through integration (2024–25)

Sharon PC

Happi; AlchemPro

Shagufta Nahid

Head of Procurement – Global (Aroma & Personal Care)

Since Apr-2026

Unilever (Senior Procurement Manager, Personal Care South Asia); PepsiCo, IKEA, BP, DuPont

HR Today

Mahesh Dicholkar

Head of HR – Manufacturing

Since Jul-2026

—

HR Today

Simon Cull

Sustainability contact (UK)

——

Sustainability Report

“—” = not publicly disclosed.

Board of Directors

DirectorCategory (per SR 2023-24)Notes

Harsh C. Mariwala

Non-executive

Mariwala family; founder-chairman of Marico (widely reported)

Dr. Ravindra K. Mariwala

Non-executive

Director since 5-Apr-2000 (MCA)

Rajendra K. Mariwala

Managing Director

—

Krishan Sharma

Whole-time Director

—

Arun Bewoor

Independent

—

Anita Belani

Independent

Director since 5-May-2015

Ketan Dalal

Independent

Director since 9-Aug-2021

Milind Sarwate

Independent

—

Governance Overview

Governance metricValueSource

Board size (FY2024)

8

Sustainability Report

Independent directors (FY2024)

4 of 8 (50%)

Sustainability Report

Women on board

12.5% (1 of 8)

Sustainability Report

Board meetings FY2024

6

Sustainability Report

Committees

Audit; Nomination & Remuneration; CSR; plus a Risk Management Committee reporting to the Board

Sustainability Report

Chair / CEO separation

MD (promoter) and Group CEO (professional) are separate roles. Board chair identity not disclosed.

—

Whistleblower incidents FY2024

0

Sustainability Report

Major Shareholders

HolderStakeSource

Promoter / Mariwala family group

94.38% (2023)

TheCompanyCheck (MCA)

Public / other

5.62% (2023)

TheCompanyCheck

Institutional holders (top 10)

Not applicable / not publicly disclosed. No listed float.

—

PitchBook-recorded equity deal

US$47.3m, 14-May-2025, 1 investor (identity not disclosed). Unconfirmed; possibly the promoter infusion anticipated by CRISIL.

PitchBook

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypePositioning vs. Eternis

Aroma chemicals (India)

Privi Speciality Chemicals (listed)

Direct; India's largest aroma exporter by its own claim

Larger and far more profitable (FY2026 revenue ₹2,583 crore, EBITDA margin 25.8%); pine-chemistry led

Aroma chemicals (India)

Oriental Aromatics (listed)

Direct

Smaller (FY2025 revenue ₹928 crore, EBITDA margin ~10%); camphor and terpene focus

Aroma chemicals (India)

Hindustan Mint & Agro, Keva / S H Kelkar (listed)

Partial overlap

Owler lists both as competitors; SHK is primarily a fragrance compounder

Aroma chemicals (global, captive)

Givaudan

Customer-competitor

Backward-integrated in some molecules

Aroma chemicals (global, captive)

dsm-firmenich

Customer-competitor

Makes Hedione® and other captives

Aroma chemicals (global, captive)

Symrise

Customer-competitor

Large integrated aroma-molecule producer

Aroma chemicals (global, captive)

IFF

Customer-competitor

Captive ingredients

Aroma chemicals (global, merchant)

BASF (Aroma Ingredients)

Direct

Petrochemical-integrated merchant producer of citral-based molecules

Aroma chemicals (global, merchant)

Takasago, Kao (Japan)

Direct / partial

Specialty aroma molecules

Aroma chemicals (global, merchant)

Chinese producers (various)

Direct

Price-setters in commodity molecules; dumping cited by CRISIL as a UK headwind in FY2024

Personal-care preservatives / functionals

Symrise Cosmetic Ingredients, Lonza/Arxada, Schülke & Mayr, Ashland, Clariant, Lanxess (named as category participants; no figures compiled)

Direct

Larger, global players with broader portfolios

Peer Comparison FY2025

MetricEternis (FY2024, consolidated)Privi Speciality (FY2025, consolidated)Oriental Aromatics (FY2025)

Revenue

1,9112,101928

Revenue growth YoY (%)

-62010

EBITDA

252 (derived)

45493

EBITDA margin (%)

13.22210

PAT

9418534

PAT margin (%)

4.98.83.7

R&D intensity (%)

—

Not compiled

Not compiled

“—” = not publicly disclosed.

Recent Developments

The window is approximately April 2025 to October 2026; three late-2024 items are included for context.

Not identified in public sources: * guidance revisions, litigation, regulatory penalties, layoffs or plant incidents in the window.

Company Snapshot

609

Employees

1965

Founded

Mumbai, India

Headquarters

SWOT Analysis

Strengths

  • Blue-chip customer base. CRISIL names Eternis a preferred supplier to Givaudan, IFF, Firmenich and Symrise (rationales 2022–2024).
  • Scale. Aggregate capacity of ~75,365 TPA (CRISIL Dec-2024) and production of 51,209 MT in FY2024 (Sustainability Report).
  • Multi-country manufacturing. Four Indian plants plus Leek (UK) plus Trezzo (Italy) give supply-security credentials that single-country Chinese and Indian rivals lack.
  • Process technology. A captive, fully automated hydrogen plant since 2005–09 supports high-cis hydrogenation grades (PTBCHA Super, OTBCHA Super).
  • Promoter financial support. Promoter equity funded ₹220 crore of debt prepayment in FY2022, and CRISIL repeatedly cites timely promoter liquidity support.
  • Credit quality. CRISIL A+/Stable since Oct-2023. FY2024 interest coverage was 7.02x and gearing 0.38x.
  • ESG leadership among Indian peers. EcoVadis Gold (UK) and Silver (India); CDP Climate B-; 67% renewable energy; ZLD in India; first Indian TfS member.

Weaknesses

  • Thin profitability. PAT margin was 3.4–4.9% over FY2021–FY2024, against Privi's ~8.8% in FY2025 (derived).
  • Volatile margins. Operating margin ranged 9.5–15.1% over four fiscals and fell to about 8% in Q1 FY2024 (CRISIL).
  • Product concentration. Hydrogenation products and salicylates were about half of revenue in FY2022–23 and about a third in FY2024 (CRISIL).
  • Flat organic growth. Revenue was ₹1,902 crore in FY2022 and ₹1,911 crore in FY2024, so there was essentially no growth over two years.
  • UK drag. Lower margins, energy exposure and Chinese competition (CRISIL Oct-2023). Energy intensity rose from 18.37 to 20.24 GJ/MT in FY2024, partly because the UK heat-recovery unit was out of service.
  • Disclosure opacity. No public annual report, segment data or audited consolidated statements, which limits counterparties' and investors' visibility.

Opportunities

  • Personal-care cross-selling. Selling Eternis Personal Care through the Eternis network into APAC and India; Sharon PC said it previously lacked Asian reach (Happi, Jan-2025).
  • Downstream value capture. The SO.F.I.A JV gives integrated beauty-brand solutions.
  • Low-carbon premium. LCAs on more than 80% of products and a target of low-PCF alternatives for 90% by 2028 give differentiation as F&F houses pursue Scope 3 cuts.
  • Food and flavour grade. The FSSAI licence at Kurkumbh and UK food-grade approval expected in 2025 open flavour applications.
  • China+1 sourcing. The Tennants rationale explicitly cited supply-chain de-risking.
  • New capacity. The ECPL greenfield plant (~1,000 MT) expands the portfolio.

Threats

  • Backward integration by customers. Customers who are also aroma producers (Givaudan, dsm-firmenich, Symrise) can integrate backward or squeeze prices. The Hedione® alliance ended when the partner chose not to invest.
  • Chinese overcapacity and dumping. Explicitly cited by CRISIL for FY2024.
  • Raw-material and FX volatility. Phenol and crude linkage, with imports from China subject to regulatory supply shocks (CRISIL).
  • Leverage risk. Projected debt/EBITDA of 4.72x at Mar-2025 if the promoter infusion was delayed (CRISIL).
  • Regulatory tightening. REACH, IFRA standards and preservative restrictions in cosmetics.
  • Geopolitical exposure in Israel. The Israel R&D operation is a geopolitical risk; Israel is no longer named as a manufacturing location post-rebrand.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
4-Dec-2024Completes 100% acquisition of Sharon Personal CareTransformational: second business leg; re-levers the balance sheet
13-Dec-2024CRISIL reaffirms A+/Stable / A1 on ₹765 crore facilitiesRating holds despite acquisition debt; promoter equity is a monitorable
Dec-2024Sharon PC President tells Happi the deal gives scale and Asian reachIntegration narrative
14-Feb-2025Vivek A. Karve appointed directorBoard strengthening
21-Mar-2025ECPL–EFCL amalgamation order filed with ROCLegal simplification complete
28-Mar-2025Strategic collaboration with ChainCraft on low-carbon bio-based aroma chemicalsSustainability / innovation
14-May-2025PitchBook records a US$47.3m equity deal (unconfirmed)Possibly the promoter infusion to deleverage
28-May-2025Joins Together for Sustainability (company news date; trade coverage 1-Jul-2025)First Indian TfS member; customer-facing ESG credential
1-Jun-2025Hari Menon joins as Global CHROProfessionalisation / cultural transformation
6-Jun-2025AGM held; FY2025 financial statements filed with ROCStatutory
25-Jun-2025Shailendra Arora appointed Whole-time DirectorExecutive bench
~Jun-2025Second sustainability report (FY2024, GRI-referenced) published67% renewable energy; CDP and EcoVadis scores disclosed
~Jul-2025Sharon PC by Eternis inaugurates the SPC-1 Trezzo plant (7,500 t/yr)Capacity in personal care
28-Aug-2025Corporate update "Enriching Lives With Care" (purpose campaign)Brand repositioning
2025–26SO.F.I.A Cosmétiques strategic JV announcedDownstream move into finished beauty manufacturing
Nov-2025Deadline in CRISIL's base case for promoter equity and 40–50% acquisition-debt prepaymentKey credit monitorable; outcome not publicly confirmed
13-Nov-2025CRISIL withdraws ECPL rating after the merger; reiterates parent at A+/StableConfirms rating stability
31-Mar-2026FY2026 closes; Tofler indicates standalone revenue band of ₹1,500–1,750 crore (+5.6%)Modest standalone growth
Apr-2026Shagufta Nahid (ex-Unilever) appointed Head of Procurement – GlobalProcurement transformation across Aroma and Personal Care
1-Jul-2026Sharon Personal Care renamed Eternis Personal Care; Robert Monti PresidentIntegration completed
Jul-2026Texture Selector formulation tool launched (personal care)Product innovation
Jul-2026Mahesh Dicholkar appointed Head of HR – Manufacturing (Daund)Manufacturing workforce focus amid expansion

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment (%): Exports as % of consolidated turnover held from 75% in FY2022 to 75% in FY2024.
Eternis Fine Chemicals Ltd. — Revenue by Segment (%)
Series (%)FY2022FY2023FY2024
Exports as % of consolidated turnover757575

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.